{"id":"ec-aspirin-325","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Bruising/bleeding"}]},"_chembl":{"chemblId":"CHEMBL25","moleculeType":"Small molecule","molecularWeight":"180.16"},"_dailymed":{"setId":"9f9355f7-024a-4adc-bb4c-2d9c0dd0cb77","title":"ASPIRIN 325 MG EC (ASPIRIN) TABLET [PROFICIENT RX LP]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin irreversibly acetylates cyclooxygenase (COX) enzymes in platelets, blocking thromboxane A2 synthesis and preventing platelet aggregation. The enteric coating delays dissolution until the drug reaches the small intestine, reducing gastric irritation while maintaining antiplatelet efficacy. This formulation is designed to provide cardiovascular protection with improved gastrointestinal tolerability.","oneSentence":"EC Aspirin 325 is an enteric-coated formulation of aspirin that inhibits platelet cyclooxygenase to prevent blood clots and reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:28.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)"},{"name":"Reduction of cardiovascular risk in patients at risk for thrombotic events"}]},"trialDetails":[{"nctId":"NCT00961350","phase":"PHASE3","title":"A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":530},{"nctId":"NCT00960869","phase":"PHASE3","title":"Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":519},{"nctId":"NCT00995410","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Aspirin-Associated Gastric Ulcers","enrollment":380},{"nctId":"NCT01557335","phase":"PHASE1","title":"A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540","status":"COMPLETED","sponsor":"POZEN","startDate":"2010-11","conditions":"Platelet Aggregation","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"EC Aspirin 325","genericName":"EC Aspirin 325","companyName":"POZEN","companyId":"pozen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EC Aspirin 325 is an enteric-coated formulation of aspirin that inhibits platelet cyclooxygenase to prevent blood clots and reduce inflammation. Used for Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke), Reduction of cardiovascular risk in patients at risk for thrombotic events.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}